【LWBP NEWS】Next-Generation Highly Selective JAK1 Inhibitor LW402 Enrolls First Patient in Phase 2 Clinical Trial for Vitiligo Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of oral LW402 tablets for the evaluation of efficacy and safety in patients with non-segmental vitiligo h... Company News Jun 3, 2026
【LWBP NEWS】Next-Generation Highly Selective JAK1 Inhibitor LW402 Enrolls First Patient in Phase 3 Clinical Trial for Atopic Dermatitis (AD) Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial of LW402 for the evaluation of efficacy and safety in patients with moderate-to-severe atopic dermatitis ... Company News Mar 18, 2026
【LWBP NEWS】World's First Bi-functional, Dual-Target Drug for Complete Cure of Hepatitis B, LW231 successfully enrolls the first subject of Phase Ib/II Clinical Trial Recently, the multi-center Phase Ib/II clinical trial of LW231 – the world's first bi-functional and dual-target drug independently developed by Longwood for complete cure of hepatitis B – has success... Company News Nov 20, 2025
【LWBP News】Dr. Zhe Wang Invited to Attend the Pre-Conference Meeting of BIO-FORUM2025 and Deliver a Keynote Speech Recently, Dr. Zhe Wang, Founder of Longwood Biopharmaceuticals, was invited to attend the Pre-Conference Meeting of BIO-FORUM2025 (Shanghai International Biotechnology and Pharmaceutical Symposium) - ... Company News Nov 3, 2025
【LWBP NEWS】Longwood Biopharmaceuticals Secures Hundreds of Millions of RMB in Series B+ Financing to Accelerate Core Pipeline Clinical Research and Global Layout Recently, Shanghai Longwood Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Longwood Biopharmaceuticals”) announced the completion of its Series B+ financing round, raising hundreds of milli... Company News Oct 29, 2025
【LWBP NEWS】 World's First Bi-functional, Dual-Target Drug for Complete Cure of Hepatitis B, LW231 Officially Initiates Phase Ib/II Clinical Trial Recently, the Phase Ib/II multi-center clinical trial of LW231, the world's first dual-function, dual-target Class 1 new drug for the complete cure of hepatitis B independently developed by Longwood B... Company News Oct 28, 2025
【LWBP NEWS】LWBP's independently developed bi-function hepatitis B new drug-LW231 participated at the 11th China (Shanghai) International Technology Fair Recently, LWBP's independently developed new hepatitis B drug LW231 was unveiled at the 11th China (Shanghai) International Technology Fair, attracting widespread attention. About LW231 LW231 is the w... Company News Jun 11, 2025
【LWBP NEWS】Next-generation oral JAK1-selective inhibitor LW402 clinical phase II study in Atopic Dermatitis completes enrollment of all subjects Recently, LW402, a new-generation oral JAK1-selective inhibitor independently developed by LWBP, has completed the enrollment of all subjects in a Clinical II study of atopic dermatitis (AD). Blinded ... Company News Jun 18, 2024
【LWBP NEWS】LW402, a new-generation oral JAK1 selective inhibitor, demonstrated amazing results in clinical phase II study for rheumatoid arthritis Recently, LWBP released the results of a clinical phase II study of LW402, a self-developed next-generation oral JAK1 selective inhibitor, in rheumatoid arthritis (RA). The results of the clinical stu... Company News Jun 18, 2024
【LWBP NEWS】LW402, a next-generation oral JAK1-selective inhibitor independently developed by LWBP, was approved for clinical studies in vitiligo Recently, LW402 was approved to conduct clinical studies in vitiligo. LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP. The safety and efficacy of LW402 have ... Company News Mar 8, 2024
【LWBP NEWS】LWBP Releases Updated Data on LW231, a Self-Developed Novel Hepatitis B Drug, at AASLD2023-The Liver Meeting Recently, Shangha i Longwood Biop harmaceutical s (LWBP) shared the latest research poster of LW231, a self-developed novel Hepatitis B drug, at AASLD2023-The Liver Meeting held in Boston, USA. As the... Company News Nov 16, 2023
【LWBP NEWS】LWBP was awarded "Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise - Biomedical Sector" On 30th October, the "Award Ceremony for Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise" was held at the Grand Neo Bay Science and Innovation Building, hosted by the Minhang Dis... Company News Nov 1, 2023